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Background: Insertion of a ventriculoperitoneal shunt (VPS) for the treatment of hydrocephalus is one of the most
common neurosurgical procedures in the UK, but failures caused by infection occur in approximately 8% of primary
cases. VPS infection is associated with considerable morbidity and mortality and its management results in
substantial cost to the health service. Antibiotic-impregnated (rifampicin and clindamycin) and silver-impregnated
VPS have been developed to reduce infection rates. Whilst there is some evidence showing that such devices may
lead to a reduction in VPS infection, there are no randomised controlled trials (RCTs) to support their routine use.
Methods/design: Overall, 1,200 patients will be recruited from 17 regional neurosurgical units in the UK and
Ireland. Patients of any age undergoing insertion of their first VPS are eligible. Patients with previous indwelling VPS,
active and on-going cerebrospinal fluid (CSF) or peritoneal infection, multiloculated hydrocephalus requiring
multiple VPS or neuroendoscopy, and ventriculoatrial or ventriculopleural shunt planned will be excluded. Patients
will be randomised 1:1:1 to either standard silicone (comparator), antibiotic-impregnated, or silver-impregnated VPS.
The primary outcome measure is time to VPS infection. Secondary outcome measures include time to VPS failure of
any cause, reason for VPS failure (infection, mechanical failure, or patient failure), types of bacterial VPS infection
(organism type and antibiotic resistance), and incremental cost per VPS failure averted.
Discussion: The British antibiotic and silver-impregnated catheters for ventriculoperitoneal shunts multi-centre
randomised controlled trial (the BASICS trial) is the first multi-centre RCT designed to determine whether antibiotic
or silver-impregnated VPS reduce early shunt infection compared to standard silicone VPS. The results of this study
will be used to inform current neurosurgical practice and may potentially benefit patients undergoing shunt surgery
in the future.
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Hydrocephalus affects one in every 500 births, and is thus
one of the most common causes of developmental disabil-
ities in children. The condition also affects older children
and adults of all ages and can be secondary to a variety of
causes including intracranial tumours, haemorrhage, and
infection. In the late 1950s, the development of treatment
with cerebral shunts revolutionised the management of
these patients. Standard treatment for hydrocephalus re-
mains the ventriculoperitoneal shunt (VPS), which is com-
posed of silicone tubing and a valve and which drains
cerebrospinal fluid (CSF) from the ventricles into the peri-
toneal cavity. Insertion of a VPS for hydrocephalus is now
one of the most common procedures performed in neuro-
surgical units, and between 3,000 and 3,500 shunt opera-
tions are carried out in adults and children per year in the
UK [1]. Shunt failure due to infection has plagued this
neurosurgical advance ever since it was developed. The in-
cidence of shunt infection varies markedly in the literature
from 3 to 27% [2-6] and is higher in certain groups, for
example neonates, children under 1 year old, and pa-
tients treated with a previous temporary external ven-
tricular drain (EVD). Episodes of shunt infection have
a significant impact on patients, in terms of health-
related quality of life, cognitive function and IQ [7],
and survival, with the number of shunt infections be-
ing an independent predictor of death in patients re-
quiring CSF shunts (HR 1.66, 95% CI: 1.02 to 2.72) [8].
Impacts on health services are also significant; these
include the requirement for prolonged inpatient hospi-
talisation, additional surgery to remove the infected
hardware, placement of a temporary EVD (a temporary
tube placed in the ventricles that are prone to infec-
tion), intravenous and intrathecal antibiotics, and fur-
ther surgery to place a new shunt once the infection
has been treated.
Currently there are three types of shunt catheter available:
standard, antibiotic-impregnated, and silver-impregnated.
There is no evidence on their comparative effectiveness,
and consequently practice is variable across the UK and
worldwide, with selection being according to surgeon
preference. The three main types of VPS catheters on
the market are:
1. Standard VPS made of silicone.
2. Antibiotic-impregnated VPS made of silicone and
impregnated with antibiotics (0.15% clindamycin and
0.054% rifampicin). This type has been on the
market for approximately 9 years and has been
adopted by the neurosurgical community as a means
to potentially reduce shunt infection, despite the fact
that it is more expensive and evidence is lacking. A
recently published systematic review and meta-
analysis of antibiotic-impregnated VPS identified onerandomised controlled trial (RCT) and 11 observa-
tional studies. The RCT, conducted in a single centre
in South Africa, demonstrated a trend favouring the
antibiotic-impregnated VPS compared to standard
VPS, but did not show a statistically significant
difference between the two groups in the risk of
shunt infection (RR: 0.38, CI: 0.11, 1.30; P = 0.12);
however, a meta-analysis of the 11 observational
studies showed a statistically significant difference
favouring the antibiotic-impregnated VPS (RR: 0.37,
CI: 0.23,0.60; P <0.0001) [9]. Research on antibiotic-
impregnated VPS in Liverpool has shown that over a
2-year period the infection rate was reduced in
paediatric patients compared to historical controls
[10]. However continued data collection over
3.5 years and published as part of a Liverpool-led
multi-centre observational study with two other UK
paediatric neurosurgical units showed no significant
reduction in infection in Liverpool [11]. Indeed the
reduction in infection achieved by antibiotic-
impregnated VPS in the multi-centre observational
study was only seen in neonates and was heavily
weighted by the results from one unit. This latter
study [11] was not part of the published systematic
review [9].
3. Silver-impregnated VPS made of silicone and
impregnated with silver. This type was launched in
the UK in March 2011 with similar infection claims.
There is little doubt that silver ions have
antimicrobial effects and they elute from silver-
impregnated catheters. However the efficacy of
silver-impregnated catheters at preventing VPS in-
fections is not yet proven. There is one observational
study of silver-impregnated VPS used to successfully
treat seven patients with active CSF infection [12].
There are no observational studies comparing the
silver-impregnated VPS infection rate with either the
standard or antibiotic-impregnated VPS. However, in
a RCT of EVDs in children and adults, silver-
impregnated EVDs have been shown to reduce
infection from 21.4% (30/140) to 12.3% (17/138)
(P = 0.042) [13]. Two further observational studies
comparing standard to silver-impregnated EVDs
have also shown a reduction in infection rates
[14,15]. The commentary accompanying the EVD
study acknowledges the need for a RCT to study the
relative benefits of silver-impregnated catheters.
Data from the UK shunt registry (to which most
neurosurgical units contribute) show that 15% of shunt
revisions are for infection [16]. In the largest rando-
mised controlled shunt trial worldwide, the infection
rate was 8.4% for primary VPS [17]. The commonest
pathogens detected are Staphylococcus species, but in a
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ganism is never determined, especially if they have
already received antimicrobial treatment or the organ-
ism is very slow growing, hampering microbiologically
directed treatment selection. However newer molecu-
lar approaches are increasing the diagnostic rate for
a range of central nervous system (CNS) infections.
Whilst a systematic review [9] suggests that antibiotic-
impregnated shunts may be an effective way of redu-
cing the incidence of shunt infections, there is some
evidence that antibiotic-impregnated VPS that become
infected may be more difficult to treat leading to pro-
longed hospital stays [18]. Antibiotic-impregnated VPS
prevent the sensitive organisms causing infection and
may allow the rifampicin-resistant organisms to sur-
vive. Subsequently this may contribute to VPS failure
secondary to infection. A second follow-up report of
500 antibiotic-impregnated primary and revision VPS
insertions showed sensitive organisms may still cause
infection but presentation was significantly delayed
compared to standard historical controls [19]. It is
plausible to suggest that antibiotic-impregnated VPS
may lead to a delay in presentation allowing increased
time for biofilm development on the ventricular sur-
face rather than just the VPS. This could result in more
difficult to treat, serious infection through rifampicin
resistance, and warrants further investigation.
There are no economic evaluations of VPS, however
four retrospective cost studies from the USA [20-23],
which include both adults and children, suggest that cost
savings may be possible through reduction of infection
with antibiotic-impregnated shunts. Approximately 70%
of shunt operations in the UK are with antibiotic-
impregnated shunts (which cost £359) and there is likely
to be a significant uptake of silver-impregnated (£365)
shunts by neurosurgeons despite the lack of evidence of
clinical benefit. Both VPS catheters cost more than
standard (£137). The potential beneficial effect on health
status of these impregnated catheters is reduced shunt
infection and its negative sequelae. This must be bal-
anced against the possibility of selecting out resistant or-
ganisms or rendering infections more difficult to treat
with adverse impact on outcome and increased cost for
impregnated VPS. The British antibiotic and silver impreg-
nated catheters for ventriculoperitoneal shunts multi-
centre randomised controlled trial (the BASICS trial) was
therefore funded to determine whether these impregnated
VPS reduce early infection, compared with standard VPS,
and whether this is cost-effective.
Primary objective
To determine whether antibiotic or silver-impregnated
VPS reduce infection compared to standard VPS follow-
ing insertion of the first de novo VPS.Secondary objectives
 To determine the proportion of first VPS infections
occurring >6 months after insertion of de novo VPS.
 To determine whether antibiotic or silver-
impregnated VPS reduce shunt failure of any cause
compared to standard VPS following insertion of
de novo VPS.
 To assess whether the reason for shunt failure is
different across the three different types of VPS.
 To determine which organisms and their resistance/
sensitivities subsequently infect these three
alternative VPS.
 To determine whether antibiotic or silver-
impregnated VPS reduce infection following the first
(non-infected) clean VPS revision for mechanical
failure compared to standard VPS.
 To assess the impact of VPS infection on the patient
in terms of quality of life.
 To assess the cost-effectiveness of antibiotic-
impregnated and silver-impregnated VPS compared
to standard VPS.
Methods/design
Design overview
The BASICS trial is a national three-arm, multi-centre,
phase III RCT comparing antibiotic-impregnated, silver-
impregnated, and standard VPS in patients with hydro-
cephalus undergoing insertion of their first permanent
shunt. The design of the trial is presented in Figure 1.
Research setting
The trial will be conducted across 17 paediatric and
adult regional neurosurgery units in the UK and
Ireland. A feasibility survey completed by 14 centres
provided information on the number of eligible hydro-
cephalus patients and confirmed that the sample size
is achievable.
Funding and ethics approval
The BASICS trial is funded by a £2.04 m grant from the
National Institute of Health Research Health Technology
Assessment (NIHR-HTA) programme. CLM is the chief
investigator and MDJ is the co-chief investigator. The
study protocol, patient information sheets, and consent
forms have received ethical approval from the North
West Greater Manchester Research Ethics Committee
(reference: 12/NW/0790).Study population
The trial will be open to all patients (children and
adults) with hydrocephalus requiring treatment with a
first permanent VPS who meet the eligibility criteria.
Figure 1 Flow diagram for trial.
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 Hydrocephalus of any aetiology (including idiopathic
intracranial hypertension) requiring first VPS.
 Failed primary endoscopic third ventriculostomy
allowed.
 Previous indwelling EVD allowed.
 Previous indwelling ventricular access device
(for example Ommaya or Rickham reservoir or similar)
allowed.
Exclusion criteria
 Evidence of CSF infection prior to surgery for
first VPS.
 Previous indwelling VPS.
 Active and on-going CSF or peritoneal infection.
 Multiloculated hydrocephalus requiring multiple
VPS or neuroendoscopy.
 Ventriculoatrial or ventriculopleural shunt planned. Allergy to antibiotics associated with the
antibiotic shunt.
Primary outcome measure
Time to VPS infection following insertion of first de
novo VPS for hydrocephalus.
Secondary outcomes
 Time to shunt failure of any cause.
 Reason for shunt failure (infection, mechanical
failure, patient failure, or other).
 Types of bacterial shunt infection (organism type
and antibiotic resistance).
 Time to shunt infection following first
clean revision.
 Quality of life.
 Incremental cost per shunt failure averted.
 Incremental cost per quality-adjusted life-year
(QALY) gained.
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Patients will be randomised to standard, antibiotic, or
silver-impregnated VPS in a ratio of 1:1:1. These are all
CE marked medical devices used in accordance with the
manufacturer’s instructions for their intended purpose.
Written informed consent and assent, where appropri-
ate, will be obtained pre-operatively, but randomisation
will not occur until the trial participant is in the theatre
suite so that only patients demonstrating continuing eli-
gibility will be randomised at this stage, avoiding the
randomisation of ineligible patients as far as is practic-
ally possible. Theatre staff cannot be blinded to the type
of shunt inserted, but once the shunt is in position there
will be no visible indications of the shunt type used. The
type of shunt inserted will not be disclosed outside the
operating theatre. Training on non-disclosure of shunt
type will be provided to all staff members present at sur-
gery. The majority of shunt revisions and removals for in-
fection happen as emergencies and are managed by the
on-call team. The likelihood of the same surgeon who
inserted the shunt being involved in the decision to re-
move the shunt is low given the work rotas of surgical
staff. However, this will be tracked by logging the staff in-
volved in surgery and in the decision to remove the shunt.
This process is the same as that successfully implemented
for the catheter infections in children (CATCH) trial
(ISRCTN34884569) and will form part of the trial moni-
toring report presented to the trial management group.
Proposed sample size
Approximately 30% of new VPS will fail within the first
6 months of insertion due to shunt complications, which
will include infection but also malfunction and mechan-
ical failure, typically secondary to catheter or valve ob-
struction and peritoneal complications. When a VPS has
failed for reasons other than infection then this prevents
infection being observed. Infection is the event of inter-
est with all other reasons for shunt failure being compet-
ing risks. The trial will compare antibiotic-impregnated
versus standard VPS, and silver-impregnated versus
standard VPS. A Bonferroni adjustment has been made
to allow for the multiple comparisons and a statistical
significance level of 0.025 will be used accordingly. The
sample size calculation is based on Pintilie [24] assuming
time to any type of event (of interest or competing risks)
follows an exponential distribution. Using a 2-year ac-
crual period with 6-month follow-up, once accrual has
been completed and a competing risks event rate of 30%
across trial arms with the event rate of interest (infec-
tion) being 8% in the standard arm and 4% in the treated
arms (hazard ratio of 0.49), then with 5% loss to follow-
up we would require 989 patients to provide 80% power.
The power varies according to changes in the event rate
with a fixed total sample size of approximately 1,143.Allowing for 5% loss to follow-up a sample size of 1,200
participants allows a hazard ratio of 0.49 to be detected
over a range of baseline event rates (0.05 to 0.1) with good
statistical power. The value of 8% is supported elsewhere
[17], in addition, infection rate surveillance over 10 years
(1993 to 2003) at Great Ormond Street Hospital, London,
UK, involving over 1,500 insertions has demonstrated that
while there are fluctuations in monthly infection rates that
overall the rate has remained remarkably stable around
this level. Observed fluctuations in infection rates within a
centre will be influenced by the size of the denominator.
Reduction of infection is a priority and therefore it could
be argued that much smaller differences than those the
study is powered to detect are still important. However
the investigators believe that a strong effect is required to
inform clinical practice and establish a first-line treatment
policy across the National Health Service (NHS). This is
in part due to the large differences in cost between the
VPS; we need to warrant expenditure on the type of VPS
as opposed to other infection control activities.
Statistical analysis
The primary analysis will be by intention-to-treat principle
as far as is practically possible and a full statistical analysis
plan will be developed prior to comparative analysis. Re-
sults will be presented throughout using 97.5% confidence
intervals and a 2.5% level of statistical significance. Analysis
of the primary outcome will be by cumulative incidence.
The Fine and Gray [25] regression method will be used to
directly model the cumulative incidence function. In
addition two semi-parametric models described in Scheike
and Zhang [26] will be used to consider time-varying ef-
fects. Time-to-event outcomes where competing risks is
not an issue will be analysed using Kaplan–Meir curves,
log-rank tests, and Cox proportional hazard models. As-
sumptions of proportional hazards will be investigated.
Categorical outcomes will be analysed using Chi-squared
test. An interim analysis will be conducted halfway through
the trial after approximately 50% of the total events have
been observed using Haybittle [27].
Heath economic analysis
The health economic analysis will adopt the perspective of
the NHS in the UK and personal social services. Costs will
include those of the catheters, duration of intensive care
stay and hospital admission, antibiotic treatment, and con-
tact with health professionals and social services. Re-
source use will be based on entries made in designated
sections of patients’ case report forms which will in-
clude questions on use of personal social services [28],
complemented with hospital.
Hospital Episode Statistics (HES) data will be sourced
from the NHS Information Centre. Unit cost data will be
obtained from routine hospital data (NHS reference costs)
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nomic question under consideration is one of technical effi-
ciency (that is, the aim to maximise health outcomes given
the resource inputs), we shall approach this as a cost-
effectiveness analysis, based on the incremental cost per
shunt failure averted. Secondary economic outcomes will
include: 1) incremental cost per shunt infection avoided;
and 2) incremental cost per QALY gained, estimated by ad-
ministering the EuroQol (Rotterdam, Netherlands) EQ-5D-
3 L, EQ-5D-Y (youth version), or Health Utilities Index
Mark 2 (HUI2; Dundas, ON, Canada) to patients (or their
parents, according to age) at each follow-up visit. Costs and
benefits occurring after the first year will be discounted at
3.5% per annum. Total costs will be combined with the
measures of health outcome to calculate the incremental
cost-effectiveness (utility) ratios of each technology. Where
appropriate, missing resource use or health outcome data
will be imputed. The number of QALYs experienced by
each patient will be calculated as the area under the curve,
using the trapezoidal rule, and corrected for baseline utility
score. Non-parametric bootstrapped 95% confidence inter-
vals will be estimated (10,000 replicates). We will also em-
ploy parametric approaches for analysing cost and QALY
data that assume normal distributions given the large sam-
ples where the near-normality of sample means is approxi-
mated. Should the data indicate otherwise, we will develop
a generalised linear model to deal with problems such as
skewness. Stratified cost-effectiveness analyses will be con-
ducted on important, pre-specified patient subgroups (in-
cluding neonates, patients under 1 year old, and patients
with a previous EVD). Cost-utility estimates will be com-
pared with the £20,000 to £30,000 per QALY threshold of
cost-effectiveness, specified by National Institute for Health
and Care Excellence (NICE), and a range of one-way sensi-
tivity analyses will be conducted to assess the robustness of
the analysis. Multivariate sensitivity analyses will be ap-
plied where interaction effects are suspected, for instance
in the assessment of the combined effect of development
of resistant organisms and the costs associated with their
management. The joint uncertainty in costs and benefits
will be considered through the application of bootstrap-
ping and the estimation of cost-effectiveness acceptability
curves [32].
Translational research studies
The study has ethical approval and funding to obtain an
additional 5 mL of blood and CSF gifted by patients at
VPS insertion and revision. These samples will be stored
until trial completion and then used for research studies
to characterise the blood and CSF patterns of host re-
sponse during confirmed shunt infection (via molecular
methods including proteomics and transcriptomics), with
an aim to use these patterns to strengthen the diagnosis of
shunt infections and improve pathogen detection.Dissemination of results
The communication and dissemination strategy will ac-
tively involve participating centres, their staff and ser-
vice users, professional bodies involved (Society of
British Neurological Surgeons, SBNS), and relevant
charitable organisations (spina bifida, hydrocephalus,
information, networking, equality, Shine). Communica-
tion and dissemination of results will be assisted by
members of the study team, including using social net-
working sites. Findings of the trial will also be presented
at national and international meetings of relevant pro-
fessional bodies and research groups. The results of the
trial will be published in peer-reviewed journals.
If the trial favours a particular impregnated catheter,
we will initiate a forum for discussion with other special-
ties such as neurologists, microbiologists, and infection
control specialists and industry to discuss the implica-
tions for practice for research into impregnated catheters
for other patient groups requiring implants in the cen-
tral nervous system, such as baclofen pumps and cathe-
ters, spinal cord stimulators, and deep brain stimulation.
Discussion
This protocol describes the design of a RCT to evaluate the
clinical effectiveness and cost-effectiveness of antibiotic-
and silver-impregnated catheters to reduce VPS infection.
This is the first RCT to compare these catheters with con-
ventional non-impregnated silicone catheters. This study
will generate one of the largest CSF and blood biobanks in
a cohort of hydrocephalus patients.
Trial status
The trial opened for recruitment in June 2013 (www.
basicsstudy.org.uk). Up to 30 November 2013, eight cen-
tres have opened and 49 patients have been randomised.
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